This week on the podcast Dr. Jack Cush reviews the news, regulatory announcements and novel journal reports including a profile on pseudogout, the safety of immune checkpoint inhibitors in RA patients and the diagnostic importance of neutrophils.

Senescence pathways are involved in giant cell arteritis (GCA), an analysis of patient tissue samples suggested, which may account for the efficacy of one agent now used for the disease and another in commercial development.

Collaboration has proven to be an essential ingredient for progress and innovation in rheumatology. Effective collaboration requires generosity with your time and resources. Here are some things that I’ve learned over the years about successful collaborations in rheumatology.

A systematic review of published literature on psoriatic arthritis (PsA), clinical features, disease activity, and patient-reported outcomes (PROs) shows generally higher levels of disease activity in women, compared to men with PsA. A metanalysis of published reports on adults with PsA, clinical variables and outcomes identified 31 publications of 27 unique studies.

Amgen Inc convinced a U.S. appeals court on Wednesday to uphold patents that bar generic versions of its blockbuster psoriasis drug Otezla proposed by Zydus Pharmaceuticals and Novartis AG's Sandoz Inc until 2028. The U.S. Court of Appeals for the Federal Circuit affirmed a New Jersey federal court's ruling that Amgen patents covering the drug were valid and that the proposed generics would infringe them.

In this session, our panelists addressed the big questions of: "How do I choose between private practice and academia?" and "How do I advance in my career?".